ALS Limited reported a 25.8% jump in underlying net profit after tax to AUD 381.2 million for FY26, driven by strong commodity testing demand and margin expansion. The company raised its dividend and advanced major hub lab projects while navigating a post-year-end cyber incident.
ALS Limited has posted a robust first half for FY26 with underlying EBIT growth of 14.7%, driven by strong performance in its Commodities segment and improved Life Sciences results. The company also raised its interim dividend and updated its growth outlook for the year.